Skip to content

Multimodal MRI-Based Quantification of Intratumoral Heterogeneity for Predicting Molecular Subtypes and Prognosis in Breast Cancer

Multimodal MRI-Based Quantification of Intratumoral Heterogeneity for Predicting Molecular Subtypes and Prognosis in Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129149
Enrollment
Unknown
Registered
2026-07-31
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sponsors

Zhejiang Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged 18 years or older who were diagnosed with invasive breast cancer through postoperative pathological examination; 2.The patient was initially diagnosed with primary breast cancer and has undergone unilateral total mastectomy or breast-conserving surgery. There is no history of other malignant tumors in the past. 3.The patient's clinical, pathological and imaging data are complete.

Exclusion criteria

Exclusion criteria: 1.Those whose clinical, pathological and imaging data are missing or incomplete; 2.Received any anti-tumor treatment (such as chemotherapy, radiotherapy, targeted therapy, surgical treatment, etc.) before the MRI examination; 3.Poor image quality, incomplete sequences, etc., make it impossible to accurately depict. 4.Has a history of breast cancer or other malignant tumors in the past; 5.Missing follow-up data;

Design outcomes

Primary

MeasureTime frame
No recurrence survival period;Prediction of molecular subtypes of breast cancer;

Countries

China

Contacts

Public ContactWang Shiwei

Zhejiang Provincial Hospital of TCM

247472554@qq.com+86 571 87070285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026